Back to top
more

BioTime, Inc. (BTX)

(Delayed Data from AMEX)

$1.26 USD

1.26
625,080

0.00 (0.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.26 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioTime (BTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1

by Zacks Equity Research

Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.

BioTime (BTX) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

BioTime (BTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Top Ranked Momentum Stocks to Buy for April 2nd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 2nd

Earnings Preview: BioTime (BTX) Q3 Earnings Expected to Decline

by Zacks Equity Research

BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nalak Das headshot

Yields on US Treasury Notes Hit Record High: 5 Bank Picks

by Nalak Das

A hike in interest rate will raise the cost of funds, which in turn will enable the financial sector, especially banks

    Can The Uptrend Continue for BioTime (BTX)?

    by Zacks Equity Research

    Investors certainly have to be happy with BioTime, Inc. (BTX) and its short term performance.

      BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      BioTime (BTX) delivered earnings and revenue surprises of 33.33% and 671.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        BioTime (BTX) in Focus: Stock Moves 7.3% Higher

        by Zacks Equity Research

        BioTime (BTX) was a big mover last session, as the company saw its shares rise more than 7% on the day.

          BioTime (BTX): Moving Average Crossover Alert

          by Zacks Equity Research

          BioTime, Inc. (BTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

            BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session

            by Zacks Equity Research

            BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.

              Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

              by Zacks Equity Research

              Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

                Try Rising P/E Investing With 5 Top-Ranked Stocks

                by Zacks Equity Research

                Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

                  Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

                  by Zacks Equity Research

                  Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

                    Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks

                    by Zacks Equity Research

                    Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

                      Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

                      by Zacks Equity Research

                      Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

                        Swarup Gupta headshot

                        5 Affordable Breakout Stocks Offering Excellent Returns

                        by Swarup Gupta

                        If properly implemented, such a strategy has the ability to deliver impressive returns.

                          Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1

                          by Zacks Equity Research

                          Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.

                            Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

                            by Zacks Equity Research

                            Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

                              Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised

                              by Zacks Equity Research

                              Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.

                                Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View

                                by Zacks Equity Research

                                Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.

                                  Infinity (INFI) Reports Narrower-than-Expected Loss in Q1

                                  by Zacks Equity Research

                                  Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.

                                    Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance

                                    by Zacks Equity Research

                                    Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.